• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • Best Managed Accounts
  • Forex Robots
  • Forex Brokers
  • Forex Signals
  • Social Trading Platforms
  • Community Reviews

  • Robots
  • Start Guide
  • Glossary
  • Basics
    • Currency Pairs
    • Charts
    • Candlesticks
    • Trading Tips
  • Strategies
    • Technical Analysis
    • Fundamental Analysis
    • Day Trading
    • Scalping
    • Swing Trading
    • Trend Following
  • News
  • Reviews
    • Forex Robots
    • Forex Brokers
  • Mustreads
  • Crypto Trading

First Long-Acting Drug Approved by FDA to Protect Infants and Toddlers from Respiratory Virus

July 19, 2023 by Forex Winner Leave a Comment

The United States officials have granted approval for the first long-acting drug that offers protection against a respiratory virus that poses a significant threat to babies and toddlers, sending a large number of American children to the hospital every year.

Respiratory Syncytial Virus (RSV) is typically a minor inconvenience for most healthy individuals, resembling a common cold. However, it can prove to be life-threatening for both the very young and elderly populations.

Best Forex Robots ›

Compare leading trading systems on the market

This approval from the Food and Drug Administration (FDA) allows for the administration of the injection to infants and children up to 2 years old, who are at an increased risk of severe RSV infections.

According to Dr. John Farley, an FDA representative, this recent approval addresses the pressing need for products that can effectively reduce the impact of RSV on children, families, and the overall healthcare system.

RSV cases surged last year, inundating hospitals across the United States with wheezing children. Currently, there are no vaccines available for babies, although companies such as Pfizer are diligently working on developing one.

AstraZeneca’s newly approved drug, to be marketed as Beyfortus, is a synthetic version of an antibody that boosts the immune system’s ability to combat RSV. As per the FDA’s approval, babies, including premature infants, can now receive a single injection to safeguard against their first RSV season, which typically spans around five months. Furthermore, children up to the age of 2 can receive an additional dose to protect them during their second encounter with the virus.

This latest development in pediatric medicine offers hope for families and healthcare professionals alike, as it tackles the significant health risks posed by RSV among infants and toddlers.

Beyfortus: A Promising Treatment for RSV Infection

Beyfortus, a groundbreaking treatment for RSV infection, is set to enter the U.S. market under the reputable pharmaceutical company, Sanofi. The drug has already obtained regulatory approval in Canada, Europe, and the U.K., solidifying its status as a potent solution in combating this respiratory virus. However, Sanofi has yet to disclose the pricing details of Beyfortus in the United States.

The U.S. Food and Drug Administration (FDA) swiftly greenlit the drug based on compelling evidence from three studies. These studies convincingly demonstrated that Beyfortus effectively reduces the risk of RSV infection by an impressive 70% to 75% among infants and children aged two and younger.

In the coming weeks, Centers for Disease Control and Prevention (CDC) advisors will convene to discuss and provide recommendations on the specific target demographic for the drug. Their insight will contribute significantly to the appropriate administration of Beyfortus and ensure optimal efficacy.

It is worth noting that a similar antibody drug was granted FDA approval over two decades ago. However, its usage was limited to high-risk babies and necessitated monthly injections. Pediatricians widely acknowledge that this drug is currently underutilized, anticipating that the longer-lasting effects of AstraZeneca’s Beyfortus will catalyze an increase in uptake by medical practitioners.

Alarming statistics reveal that approximately 58,000 children under the age of five are hospitalized each year due to RSV, with several hundred tragically succumbing to the virus. Consequently, the advent of innovative treatments and preventive measures marks a significant turning point after decades of setbacks in RSV research.

In a momentous breakthrough earlier this year, pharmaceutical companies achieved remarkable progress by developing the first-ever vaccines against RSV. The FDA’s approval of RSV vaccines for older adults from GlaxoSmithKline and Pfizer in May was a monumental milestone. Looking ahead, Pfizer’s vaccine for pregnant women is anticipated to receive FDA approval in August, aiming to provide enhanced protection to their newborns.

The introduction of Beyfotus along with these other advancements offers a renewed sense of hope in the battle against RSV, ultimately paving the way for a healthier and safer future.

Best Forex Robots ›

Compare leading trading systems on the market

Filed Under: Forex News Tagged With: Beyfortus, FDA, infants, respiratory virus, RSV, toddlers, treatment

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Best Forex Robots

  1. Techberry 8.7
  2. Happy Forex 8.0
  3. Forex Fury 7.7
  4. Promax Gold EA 6.8
  5. Gump EA 6.4

Best Forex Brokers

  1. Techberry 8.7
  2. XM 8.2
  3. eToro 8.1
  4. Pepperstone 8.1
  5. IG 8.0

Latest News

PumpSwap Launched Revenue Sharing Aimed at Incentivizing Creators – Tekedia

May 15, 2025

New gas processing plant will be a game-changer for Ghana – Finance Minister – Ghanamma.com

May 14, 2025

Cold, hard truth: Alaskans lose $26M to Internet crime

May 14, 2025

Footer

Forex Broker Reviews

Tickmill Forex Broker Logo

Tickmill Review

April 23, 2019 By Forex Winner

Hot Forex

HotForex Review

November 10, 2019 By Forex Winner

CMC Markets

CMC Markets Review

November 25, 2019 By Forex Winner

Forex Robot Reviews

Earn2Trade Review

August 20, 2023 By Shandor Brenner

FundedNext Review

August 16, 2023 By Shandor Brenner

Topstep Forex Review

August 14, 2023 By Shandor Brenner

EMAIL NEWSLETTER

Sign up to receive exclusive forex trading guides and insights from our team of experts!

Copyright © 2025 · Forex Traders Guide · About Us · Contact Us
Privacy Policy · Risk Disclosure